What is BridgeBio Oncology Therapeutics, Inc.?
, a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 145.25M, and a P/E ratio of 3.4x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.